Giant-Cell Arteritis Market to Observe Stunning Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies – Novartis, Abbvie, CSL, Kiniksa Pharma, Roche, MorphoSys

March 15 11:36 2023
Giant-Cell Arteritis Market to Observe Stunning Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - Novartis, Abbvie, CSL, Kiniksa Pharma, Roche, MorphoSys
Delveinsight Business Research LLP
As per DelveInsight, the Giant Cell Arteritis Market is anticipated to evolve immensely in the coming years owing to the growing geriatric population, the rise in the prevalence of cardiovascular disorders, and technological advancements in the healthcare industry.

Several major pharma and biotech companies such as AbbVie, Novartis Pharmaceuticals, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG are involved in developing drugs for Giant cell arteritis.

DelveInsight’s “Giant-Cell Arteritis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Giant-Cell Arteritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Giant-Cell Arteritis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Giant-Cell Arteritis Market

Giant-Cell Arteritis: An Overview

Giant Cell Arteritis (GCA), also called temporal arteritis, is a vasculitis that affects large and middle-sized blood vessels with a predisposition to the involvement of cranial arteries derived from the carotid artery in individuals older than 50 years of age. It is primarily a disease of cell-mediated immunity, which is thought to arise as a maladaptive response to endothelial injury. Actinic damage to the temporal artery from chronic sun exposure has been proposed as one source of the injury.

GCA is classified as a large-vessel vasculitis but also involves medium and small arteritis, particularly the superficial temporal arteritis- hence it is termed temporal arteritis. Along with this, GCA most commonly affects the ophthalmic, occipital, vertebral, posterior ciliary, and proximal vertebral arteries. Medium- and large-sized vessels may be involved, including the aorta and the carotid, subclavian, and iliac arteries.

Giant-Cell Arteritis Market Key Facts

  • As per the estimates, the highest cases of GCA in the 7MM were in the United States, followed by the United Kingdom, France, Italy, Germany, Spain, and Japan in 2020.

  • In the United States, the total number of prevalent cases of Giant Cell Arteritis was 244,000+ cases in the year 2020.

  • In the year 2020, the total prevalent cases of Giant Cell Arteritis were 190,000+ cases in EU-5.

  • In Japan, the total number of prevalent cases of Giant Cell Arteritis was 875 cases in the year 2020.

  • As per the study by Castañeda et al. (2022), in Spain, the prevalence of GCA reported that GCA mainly affects patients older than 50 years, with a prevalence of 30.4/100,000.

  • As per the study conducted by Catanoso et al. (2017) estimated the prevalence of GCA in Italy to be around 85 per 100,000 population. The gender-based segments and clinical manifestations have also been prepared based on extensive secondary research and regional trend analysis.

Giant-Cell Arteritis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Giant-Cell Arteritis market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Giant-Cell Arteritis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Giant-Cell Arteritis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Giant-Cell Arteritis Epidemiology, Segmented as –

  • Total Age group-specific Cases of Giant Cell Arteritis in the 7MM (2019–2032)

  • Total Prevalent Cases of Giant Cell Arteritis in the 7MM (2019–2032)

  • Total Subtype-specific Cases of Giant Cell Arteritis in the 7MM (2019–2032)

  • Total Treated Cases of Giant Cell Arteritis in the 7MM (2019–2032)

  • Total Clinical Manifestation-specific Cases of Giant Cell Arteritis in the 7MM (2019–2032)

Giant-Cell Arteritis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Giant-Cell Arteritis market or expected to be launched during the study period. The analysis covers the Giant-Cell Arteritis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Giant-Cell Arteritis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Giant-Cell Arteritis Market Will Evolve and Grow by 2032 @

Giant-Cell Arteritis Therapeutics Analysis

Currently, there is just one therapy that is approved in the 7MM for the treatment of giant cell arteritis, which includes Chugai Pharmaceuticals/Roche’s Actemra/RoActemra (Tocilizumab). Several major pharma and biotech companies are developing therapies for Giant-Cell Arteritis. Novartis is leading the therapeutics market with its Giant-Cell Arteritis drug candidates in the most advanced stage of clinical development. 

The Leading Companies in the Giant-Cell Arteritis Therapeutics Market Include:

  • Novartis

  • AbbVie

  • XOMA

  • Kiniksa Pharmaceuticals

  • Eli Lilly and Company

  • Janssen Biotech

  • Dr Reddys Laboratories

  • Roche Holding

  • AbbVie

  • Novartis Pharmaceuticals

  • CSL

  • Johnson & Johnson

  • MorphoSys AG

And Many Others

Giant-Cell Arteritis Emerging and Marketed Drugs Covered in the Report Include:

  • Cosentyx (secukinumab): Novartis Pharmaceuticals

  • KPL-301 (mavrilimumab): CSL/Kiniksa Pharmaceuticals

  • Tremfya (guselkumab): Johnson & Johnson/MorphoSys AG

  • Rinvoq (upadacitinib): AbbVie

  • Actemra / RoActemra (Tocilizumab): Roche Holding

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Giant-Cell Arteritis Competitive Intelligence Analysis

4. Giant-Cell Arteritis Market Overview at a Glance

5. Giant-Cell Arteritis Disease Background and Overview

6. Giant-Cell Arteritis Patient Journey

7. Giant-Cell Arteritis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Giant-Cell Arteritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Giant-Cell Arteritis Unmet Needs

10. Key Endpoints of Giant-Cell Arteritis Treatment

11. Giant-Cell Arteritis Marketed Products

12. Giant-Cell Arteritis Emerging Drugs and Latest Therapeutic Advances

13. Giant-Cell Arteritis Seven Major Market Analysis

14. Attribute Analysis

15. Giant-Cell Arteritis Market Outlook (In US, EU5, and Japan)

16. Giant-Cell Arteritis Access and Reimbursement Overview

17. KOL Views on the Giant-Cell Arteritis Market

18. Giant-Cell Arteritis Market Drivers

19. Giant-Cell Arteritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic healthcare market today @ Healthcare Partner Identification Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

view more articles

About Article Author